NCT02232061View on ClinicalTrials.gov

Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks

PHASE4CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 29, 2014

Primary Completion Date

January 24, 2020

Study Completion Date

January 24, 2020

Conditions
Multiple Sclerosis
Interventions
DRUG

Fingolimod

Fingolimod 0.5 mg tablet

Trial Locations (4)

3500

Novartis Investigative Site, Hasselt

9000

Novartis Investigative Site, Ghent

80131

Novartis Investigative Site, Napoli

88212

Novartis Investigative Site, Ravensburg

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY